Craig-Hallum analyst John Wilkin initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $15 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies Holds Annual Shareholders Meeting
- Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress
- Adaptive Biotechnologies price target raised to $13 from $11 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Adaptive Biotechnologies price target raised to $9 from $7 at Morgan Stanley